Low Psychosine in Krabbe Disease with Onset in Late Infancy: A Case Report

Krabbe disease (KD) is a rare inherited neurodegenerative disorder caused by a deficiency in galactocerebrosidase enzyme activity, which can present in early infancy, requiring an urgent referral for hematopoietic stem cell transplantation, or later in life. Newborn screening (NBS) for KD requires i...

Full description

Bibliographic Details
Main Authors: Camille S. Corre, Dietrich Matern, Joan E. Pellegrino, Carlos A. Saavedra-Matiz, Joseph J. Orsini, Robert Thompson-Stone
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:International Journal of Neonatal Screening
Subjects:
Online Access:https://www.mdpi.com/2409-515X/7/2/28
_version_ 1797532346329595904
author Camille S. Corre
Dietrich Matern
Joan E. Pellegrino
Carlos A. Saavedra-Matiz
Joseph J. Orsini
Robert Thompson-Stone
author_facet Camille S. Corre
Dietrich Matern
Joan E. Pellegrino
Carlos A. Saavedra-Matiz
Joseph J. Orsini
Robert Thompson-Stone
author_sort Camille S. Corre
collection DOAJ
description Krabbe disease (KD) is a rare inherited neurodegenerative disorder caused by a deficiency in galactocerebrosidase enzyme activity, which can present in early infancy, requiring an urgent referral for hematopoietic stem cell transplantation, or later in life. Newborn screening (NBS) for KD requires identification and risk-stratification of patients based on laboratory values to predict disease onset in early infancy or later in life. The biomarker psychosine plays a key role in NBS algorithms to ascertain probability of early-onset disease. This report describes a patient who was screened positive for KD in New York State, had a likely pathogenic genotype, and showed markedly reduced enzyme activity but surprisingly low psychosine levels. The patient ultimately developed KD in late infancy, an outcome not clearly predicted by existing NBS algorithms. It remains critical that psychosine levels be evaluated alongside genotype, enzyme activity levels, and the patient’s evolving clinical presentation, ideally in consultation with experts in KD, in order to guide diagnosis and plans for monitoring.
first_indexed 2024-03-10T10:57:51Z
format Article
id doaj.art-b2e625b1690f44cbb0e90cbc2881fb22
institution Directory Open Access Journal
issn 2409-515X
language English
last_indexed 2024-03-10T10:57:51Z
publishDate 2021-05-01
publisher MDPI AG
record_format Article
series International Journal of Neonatal Screening
spelling doaj.art-b2e625b1690f44cbb0e90cbc2881fb222023-11-21T21:45:55ZengMDPI AGInternational Journal of Neonatal Screening2409-515X2021-05-01722810.3390/ijns7020028Low Psychosine in Krabbe Disease with Onset in Late Infancy: A Case ReportCamille S. Corre0Dietrich Matern1Joan E. Pellegrino2Carlos A. Saavedra-Matiz3Joseph J. Orsini4Robert Thompson-Stone5Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USABiochemical Genetics Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA Inherited Metabolic Specialty Center, Department of Pediatrics, Upstate Medical University, Syracuse, NY 13010, USANY State Newborn Screening Program, Wadsworth Center, New York State Department of Health, Al-bany, NY 13010, USANY State Newborn Screening Program, Wadsworth Center, New York State Department of Health, Al-bany, NY 13010, USADepartment of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USAKrabbe disease (KD) is a rare inherited neurodegenerative disorder caused by a deficiency in galactocerebrosidase enzyme activity, which can present in early infancy, requiring an urgent referral for hematopoietic stem cell transplantation, or later in life. Newborn screening (NBS) for KD requires identification and risk-stratification of patients based on laboratory values to predict disease onset in early infancy or later in life. The biomarker psychosine plays a key role in NBS algorithms to ascertain probability of early-onset disease. This report describes a patient who was screened positive for KD in New York State, had a likely pathogenic genotype, and showed markedly reduced enzyme activity but surprisingly low psychosine levels. The patient ultimately developed KD in late infancy, an outcome not clearly predicted by existing NBS algorithms. It remains critical that psychosine levels be evaluated alongside genotype, enzyme activity levels, and the patient’s evolving clinical presentation, ideally in consultation with experts in KD, in order to guide diagnosis and plans for monitoring.https://www.mdpi.com/2409-515X/7/2/28Krabbe diseasepsychosinenewborn screening
spellingShingle Camille S. Corre
Dietrich Matern
Joan E. Pellegrino
Carlos A. Saavedra-Matiz
Joseph J. Orsini
Robert Thompson-Stone
Low Psychosine in Krabbe Disease with Onset in Late Infancy: A Case Report
International Journal of Neonatal Screening
Krabbe disease
psychosine
newborn screening
title Low Psychosine in Krabbe Disease with Onset in Late Infancy: A Case Report
title_full Low Psychosine in Krabbe Disease with Onset in Late Infancy: A Case Report
title_fullStr Low Psychosine in Krabbe Disease with Onset in Late Infancy: A Case Report
title_full_unstemmed Low Psychosine in Krabbe Disease with Onset in Late Infancy: A Case Report
title_short Low Psychosine in Krabbe Disease with Onset in Late Infancy: A Case Report
title_sort low psychosine in krabbe disease with onset in late infancy a case report
topic Krabbe disease
psychosine
newborn screening
url https://www.mdpi.com/2409-515X/7/2/28
work_keys_str_mv AT camillescorre lowpsychosineinkrabbediseasewithonsetinlateinfancyacasereport
AT dietrichmatern lowpsychosineinkrabbediseasewithonsetinlateinfancyacasereport
AT joanepellegrino lowpsychosineinkrabbediseasewithonsetinlateinfancyacasereport
AT carlosasaavedramatiz lowpsychosineinkrabbediseasewithonsetinlateinfancyacasereport
AT josephjorsini lowpsychosineinkrabbediseasewithonsetinlateinfancyacasereport
AT robertthompsonstone lowpsychosineinkrabbediseasewithonsetinlateinfancyacasereport